research use only
Cat.No.S5188
|
In vitro |
DMSO
: 13 mg/mL
(23.52 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 552.63 | Formula | C27H36N8O5 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1374639-75-4 | -- | Storage of Stock Solutions |
|
|
| Synonyms | LEE011 succinate | Smiles | CN(C)C(=O)C1=CC2=CN=C(NC3=NC=C(C=C3)N4CCNCC4)N=C2[N]1C5CCCC5.OC(=O)CCC(O)=O | ||
| Targets/IC50/Ki |
CDK4
(Cell-free assay) 10 nM
CDK6
(Cell-free assay) 39 nM
|
|---|---|
| In vitro |
LEE011, as dual CDK4/CDK6 inhibitor, significantly inhibits the growth of 12 of 17 neuroblastoma cell lines with mean IC50 of 307 nM. The growth inhibition of neuroblastoma cell lines is primarily cytostatic and is mediated by a G1 cell-cycle arrest and cellular senescence. |
| In vivo |
LEE011 (200 mg/kg daily, p.o.) significantly causes tumor growth delay in mice harboring the BE2C or 1643 xenografts with no weight loss or other signs of toxicity. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03056833 | Completed | Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Carcinoma |
Ronald Buckanovich|University of Pittsburgh |
June 10 2017 | Phase 1 |
| NCT02934568 | Recruiting | Continued Access to Study Treatment(s) Cancers With a Mass Bulky Tumor Nodule Lump Advanced Cancer Advanced Solid Tumors Advanced Solid Malignancies |
Novartis Pharmaceuticals|Novartis |
December 15 2016 | Phase 2 |
| NCT02734615 | Terminated | Advanced or Metastatic ER+ Breast Cancer |
Novartis Pharmaceuticals|Novartis |
June 14 2016 | Phase 1 |
| NCT02431481 | Completed | Normal Renal Function|Impaired Renal Function |
Novartis Pharmaceuticals|Novartis |
October 23 2015 | Phase 1 |
| NCT02292550 | Completed | Non-small Cell Lung Cancer |
Novartis Pharmaceuticals|Novartis |
May 14 2015 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.